Acumen Pharmaceuticals, Inc.
General ticker "ABOS" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $89.8M (TTM average)
Acumen Pharmaceuticals, Inc. follows the US Stock Market performance with the rate: 44.9%.
Estimated limits based on current volatility of 4.1%: low 1.85$, high 2.01$
Factors to consider:
- Total employees count: 52 (+30.0%) as of 2023
- Top business risk factors: Operational and conduct risks, Funding dependency, Liquidity and credit risks, Litigation risks, Regulatory and compliance
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [1.25$, 3.28$]
- 2025-12-31 to 2026-12-31 estimated range: [1.30$, 3.33$]
Financial Metrics affecting the ABOS estimates:
- Positive: with PPE of -1.0 at the end of fiscal year the price was low
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -80.11 <= 0.33
- Negative: negative Industry operating cash flow (median)
- Positive: Shareholder equity ratio, % of 76.08 > 63.39
Short-term ABOS quotes
Long-term ABOS plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $45.24MM | $61.14MM | $114.02MM |
| Operating Income | $-45.24MM | $-61.14MM | $-114.02MM |
| Non-Operating Income | $2.38MM | $8.77MM | $11.69MM |
| Interest Expense | $0.00MM | $0.58MM | $4.07MM |
| R&D Expense | $32.36MM | $42.32MM | $93.80MM |
| Income(Loss) | $-42.86MM | $-52.37MM | $-102.33MM |
| Profit(Loss)* | $-42.86MM | $-52.37MM | $-102.33MM |
| Stockholders Equity | $188.78MM | $266.97MM | $181.82MM |
| Inventory | $0.20MM | $0.00MM | $0.16MM |
| Assets | $196.59MM | $310.12MM | $238.99MM |
| Operating Cash Flow | $-35.15MM | $-43.06MM | $-86.22MM |
| Capital expenditure | $0.16MM | $0.02MM | $0.02MM |
| Investing Cash Flow | $39.19MM | $-171.67MM | $48.03MM |
| Financing Cash Flow | $3.91MM | $151.75MM | $6.93MM |
| Earnings Per Share** | $-1.06 | $-1.08 | $-1.71 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.